苑东生物(688513.SH)：EP-0210单抗注射液I期临床试验完成首例受试者给药

Core Viewpoint - Yuan Dong Biotech (688513.SH) has announced that its wholly-owned subsidiary Chengdu Youluo Biotech Co., Ltd. has initiated a Phase I clinical trial for its self-developed monoclonal antibody EP-0210 injection, targeting inflammatory bowel disease, with the first subject having been dosed recently [1] Group 1: Product Development - EP-0210 is a humanized IgG1 monoclonal antibody targeting human tumor necrosis factor-like ligand 1A (TL1A), aimed at treating inflammatory bowel disease [1] - The mechanism of action involves high-affinity binding to TL1A, blocking the pro-inflammatory signaling pathways mediated by TL1A, thereby providing therapeutic effects for inflammatory bowel disease [1] Group 2: Clinical Research and Efficacy - Preclinical studies have demonstrated that EP-0210 has a clear mechanism of action and significant efficacy in various inflammatory bowel disease models, showing good safety and effectiveness [1] - EP-0210 exhibits superior target activity and in vivo efficacy compared to the foreign competitor RVT-3101, potentially offering safer and more effective options for patients with inflammatory bowel disease [1]